Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model.

309 Background: A prognostic model for patients with metastatic urothelial cell carcinoma (UCC) progressing following platinum-based therapy was constructed based on data from the phase 3 vinflunine trial. However, prognostic information for patients treated outside the setting of clinical trials and with variety of second-line regimens are limited. Methods: We gathered individual patient’s data from studies assessing second-line chemotherapy for metastatic UCC and analyzed the influence of factors of interest on overall survival (OS) through univariate and multivariate Cox-regression analysis. A prognostic model was constructed, and data of an independent series from a single institution was utilized for validation. Results: Data for 182 patients from seven studies were pooled. The second-line treatment was single agent in 22 (12%), platinum-based combination (nedaplatin or oxaliplatin) in 59 (33%), and non-platinum combination in 101 (55%). In multivariate analysis, Eastern Cooperative Oncology Group pe...